Cargando…
S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
Autores principales: | Costa, Luciano, Medvedova, Eva, Chhabra, Sarabh, Dholaria, Bhagirathbhai, Dhakal, Binod, Godby, Kelly, Silberman, Rebecca, Bal, Susan, D’souza, Anita, Giri, Smith, Schmidt, Timothy, Omel, James, Hari, Parameswaran, Callander, Natalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428362/ http://dx.doi.org/10.1097/01.HS9.0000967724.13321.95 |
Ejemplares similares
-
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation
por: Silbermann, Rebecca W., et al.
Publicado: (2023) -
The Quadruplets
por: Shepherd, H. L., et al.
Publicado: (1949) -
Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022) -
Case of Quadruplets
por: Miller, J. W.
Publicado: (1870) -
MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
por: Shukla, Deepak Kumar, et al.
Publicado: (2021)